Q2 FY2026 EarningsQ2 FY26 results missed consensus estimates significantly due to a $29.1M non-cash goodwill impairment in the Hiya segment and persistent weakness in active customer counts. Revenue of $223.3M fell short of the $235.0M consensus, while GAAP EPS of -$1.16 was substantially below the $0.22 expected. The Hiya segment's 16.7% YoY revenue decline and the spike in the effective tax rate further pressured the bottom line, despite modest growth in the Rise segment and stability in Greater China.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: USANA Health Sciences(USNA) the Revenue is 223.27 M (-5.33%), Miss estimate;the EBIT is -20 M (-219.6%), Miss estimate;the EPS is -1.16 (-323.1%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueMiss expectations
0.22B5.33%
0.24B0.36%
-0.01B4.97%
EBITMiss expectations
-0.02B219.61%
0.01B37.42%
-0.03B182.19%
EPSMiss expectations
-1.16323.08%
0.2257.69%
-1.3800265.39%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf